Gallbladder cancer (GBC) is associated with a sinister prognosis, a short survival time, and early metastasis to distant sites. Chronic inflammation of the gallbladder due to gallstone disease and biliary bacteria remain key factors in the pathogenesis of GBC. The association of chronic bacterial infections with the development of GBC has provided a new perspective on the causation of GBC. A strong link between chronic Salmonella infection and enterohepatic strains of Helicobacter species with GBC has been suggested. It is believed that many other enteric bacterial strains, predominantly the Enterobacteriaceae species, are associated with the development of GBC. However, the available literature mainly comprises observational studies and small meta-analyses necessitating the requirement of a higher level of evidence. This chapter discusses the role of the gut microbiome, dysbiosis and its association with carcinogenesis, and the organisms associated with the causation of GBC.
Crohn’s disease (CD) is a chronic, recurrent, immune-mediated inflammatory bowel disease that demonstrates a spectrum of intestinal and extra-intestinal manifestations. The pathogenesis of CD is multifactorial and involves a complex interplay between environmental and microbiological factors in a genetically susceptible host. There is robust evidence suggesting the role of gut microbial dysbiosis in the development as well as exacerbation of CD by immune dysregulation and alteration in the immune microbiota crosstalk. Patients with CD show reduced commensal microbial diversity, along with increased numbers of pathogenic Enterobacteriaceae and Proteobacteriaceae. Faecalibacterium prausnitzii, an anti-inflammatory molecule-producing bacteria, is also seen in reduced numbers in patients with CD and is associated with an increased risk of recurrence. There has been a paradigm shift in the management of patients of CD, from controlling symptoms to controlling inflammation and promoting mucosal healing. Current treatment strategies aim to replace, remove, reset, or redesign the gut microbiota for the therapeutic benefits of patients with CD. These include microbial restoration therapies such as dietary modification, the use of pre-, pro-, and postbiotics, and fecal microbiota transfer (FMT). This chapter focuses on the role of gut microbiota in the pathophysiology of CD and the emerging concepts in microbial therapeutics.
Purpose: Data regarding the efficacy of various radiotherapy techniques for post mastectomy chest-wall radiotherapy
(PMRT) using hypofractionation is scarce and cardiac toxicity remains a concern.This study aims to compare effect of
IMRT (Intensity Modulated Radiation Therapy) and 3D-CRT (3-Dimensional Conformal Radiation Therapy) techniques
on cardiac dose.
Materials and Methods: In this retrospective study,we compared IMRT and 3DCRT plans of 20 patients who received
PMRT to a dose of 42.56Gy/16# and the dosimetric parameters in terms of planning target volume (PTV) coverage and
dose to organ at risk (OARs) including heart and ipsilateral lung were recorded and analyzed.
Result: PTV coverage were comparable with both techniques. IMRT planning provided a better conformity index as
compared with 3DCRT (0.95 vs 0.91, p<0.001).The mean dose to the heart significantly reduced with IMRT (4.36Gy vs
8.2Gy,p<0.00001).
Conclusion: IMRT offers a significant reduction in mean heart dose than 3DCRT in patients treated with
hypofractionated post-mastectomy irradiation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.